Stuart A. A. Montgomery

Stuart A. A. Montgomery's AcademicInfluence.com Rankings

Psychology

#1589

World Rank

#1911

Historical Rank

Clinical Psychology

#93

World Rank

#93

Historical Rank

psychology Degrees

Download Badge

Psychology

Why Is Stuart A. A. Montgomery Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stuart A. A. Montgomery's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A New Depression Scale Designed to be Sensitive to Change (1979) (11956)
Social functioning in depression: a review. (2000) (505)
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. (2007) (373)
Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey (2000) (291)
Lack of Efficacy of the Substance P (Neurokinin1 Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder (2006) (282)
Selective serotonin reuptake inhibitors: meta‐analysis of discontinuation rates (1994) (256)
Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. (1997) (221)
The Prophylactic Efficacy of Fluoxetine in Unipolar Depression (1988) (216)
Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. (2006) (208)
Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. (2002) (204)
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease (2003) (197)
Pharmacological prevention of suicidal behaviour. (1982) (189)
Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression (1993) (181)
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. (2002) (181)
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? (2014) (173)
Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. (2001) (165)
A 24‐week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression (1993) (165)
Which antidepressants have demonstrated superior efficacy? A review of the evidence (2007) (160)
Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta‐analysis (1995) (153)
Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment. (2000) (153)
Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder (2001) (150)
Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. (2009) (146)
Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine (2007) (142)
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability (1997) (133)
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial (2008) (124)
Mirtazapine versus amitriptyline in the long‐term treatment of depression: a double‐blind placebo‐controlled study (1998) (121)
Antidepressants and seizures: emphasis on newer agents and clinical implications (2005) (117)
Discontinuation symptoms in depression and anxiety disorders. (2007) (117)
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine† (2014) (112)
The prevention of recurrent suicidal acts. (1983) (109)
AMITRIPTYLINE PLASMA-CONCENTRATION AND CLINICAL EFFECT A World Health Organisation Collaborative Study (1978) (106)
Humanistic and economic burden of generalized anxiety disorder in North America and Europe. (2012) (103)
A Double-Blind Comparison of Lithium Carbonate and Maprotiline in the Prophylaxis of the Affective Disorders (1976) (101)
Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder (2008) (101)
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? (2009) (101)
Continuation Therapy with Amitriptyline in Depression (1978) (99)
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder (2003) (96)
WCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults (2003) (95)
Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression (2011) (94)
A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. (2005) (93)
Thyrotrophin-releasing hormone in the treatment of depression. (1974) (92)
Development of a schizophrenia scale sensitive to change (1978) (87)
Reboxetine: additional benefits to the depressed patient. (1997) (87)
Duloxetine in the prevention of relapse of major depressive disorder (2006) (86)
A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder (2012) (85)
Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo‐controlled 6 month study (1995) (83)
The optimal dosing regimen for citalopram‐a meta‐analysis of nine placebo‐controlled studies (1994) (80)
Venlafaxine: a new dimension in antidepressant pharmacotherapy. (1993) (76)
Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice (2019) (75)
Guidelines for treating depressive illness with antidepressants (1993) (74)
The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression (2015) (74)
Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study (2018) (73)
Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample. (2017) (72)
Cardiovascular effects of amitriptyline, mianserin, zimelidine and nomifensine in depressed patients. (1979) (72)
Efficacy and tolerability of milnacipran: an overview (1996) (72)
Brain-derived neurotrophic factor gene polymorphisms: influence on treatment response phenotypes of major depressive disorder (2011) (71)
Clinically relevant effect sizes in depression (1994) (70)
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. (2016) (69)
Selective serotonin reuptake inhibitors (1994) (69)
Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. (2016) (68)
Is there a role for a pure noradrenergic drug in the treatment of depression? (1997) (67)
Pharmacotherapy of depression and mixed states in bipolar disorder. (2000) (66)
A New Prediction Model for Evaluating Treatment-Resistant Depression. (2017) (64)
Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. (2002) (63)
Venlafaxine versus placebo in the preventive treatment of recurrent major depression. (2004) (62)
Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. (2017) (62)
Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. (2013) (61)
Escitalopram versus venlafaxine XR in the treatment of depression (2006) (61)
Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder (2002) (60)
Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder (2001) (59)
Why do we need new and better antidepressants? (2006) (57)
Efficacy in long-term treatment of depression. (1996) (57)
Profiles of antidepressant activity with the Montgomery‐Asberg depression rating scale (1985) (57)
Rapid onset of action of venlafaxine (1995) (56)
Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. (2013) (56)
Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist (2006) (54)
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder (2008) (53)
The efficacy of fluoxetine as an antidepressant in the short and long term. (1989) (52)
Nortriptyline in depressed patients with high plasma levels. II (1978) (52)
SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OCD (1992) (51)
Dose Response Relationship of Citalopram 20 mg, Citalopram 40 mg and Placebo in the Treatment of Moderate and Severe Depression (1992) (50)
Social phobia: long‐term treatment outcome and prediction of response - a moclobemide study (1997) (49)
Is there a Relationship between Serotonin Receptor Subtypes and Selectivity of Response in Specific Psychiatric Illnesses? (1989) (48)
Anxiety and Depression (1990) (48)
Antidepressant efficacy in relation to item analysis and severity of depression: a placebo‐controlled trial of fluvoxamine versus imipramine (1995) (48)
Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control (2013) (47)
Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study (2011) (46)
Tolerability of Serotonin Norepinephrine Reuptake Inhibitor Antidepressants (2008) (46)
Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. (1989) (45)
Routine nortriptyline levels in treatment of depression. (1977) (45)
Efficacy of escitalopram compared to citalopram: a meta-analysis. (2011) (44)
Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. (2015) (44)
WCA Recommendations for the Long-Term Treatment of Social Phobia (2003) (44)
Amitriptyline plasma concentration and clinical response. (1979) (44)
Antidepressant Therapy at the Dawn of the Third Millennium (1999) (43)
Critical issues in the treatment of affective disorders (1995) (43)
The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia (2009) (43)
Suicide and Antidepressants (1997) (43)
A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. (1993) (42)
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD) (2018) (42)
Selecting methodologies for the evaluation of differences in time to response between antidepressants. (2002) (42)
Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study (2015) (41)
5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder (2010) (41)
The Influence of Different Relapse Criteria on the Assessment of Long‐Term Efficacy of Sertraline (1991) (40)
Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. (2002) (39)
A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression (2001) (38)
New developments in the treatment of depression. (1999) (38)
Dosage Adjustment from Simple Nortriptyline Spot Level Predictor Tests in Depressed Patients (1979) (37)
The Antidepressant Efficacy of Reboxetine in Patients with Severe Depression (2003) (37)
First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia (1995) (37)
Implications of the severity of social phobia. (1998) (36)
Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder (1992) (36)
Predicting response: noradrenaline reuptake inhibition. (1999) (35)
The duration, nature and recurrence rate of brief depressions (1990) (34)
Side effects, dropouts from treatment and cost consequences (1998) (33)
Long-Term Treatment of Depression (1994) (33)
The advantages of paroxetine in different subgroups of depression. (1992) (33)
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder (2012) (33)
PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway (2014) (33)
Clinical correlates of augmentation/combination treatment strategies in major depressive disorder (2018) (31)
Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability (2013) (31)
The antidepressant efficacy of citalopram (1996) (30)
Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies (2012) (30)
The under-recognized role of dopamine in the treatment of major depressive disorder. (2008) (29)
Fluvoxamine prevents recurrence of depression: results of a long‐term, double‐blind, placebo‐controlled study (1998) (29)
Treatment-resistant Depression: Kasper/Treatment-resistant Depression (2013) (29)
Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples (2018) (29)
Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder (2013) (29)
Neuronal cell adhesion genes and antidepressant response in three independent samples (2015) (28)
Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression. (2019) (28)
A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping (2019) (28)
Brain 5-HT function in obsessive-compulsive disorder (1997) (28)
Bipolar II disorder as a risk factor for postpartum depression. (2016) (28)
The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives (2018) (27)
Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. (2007) (27)
Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder (2010) (27)
Improving the chance of recovery from the short‐ and long‐term consequences of depression (2003) (27)
Depression: a long‐term illness and its treatment (1998) (27)
Efficacy and safety of the selective serotonin reuptake inhibitors in treating depression in elderly patients (1998) (27)
Psychopharmacology of Obsessive-Compulsive Disorder (1998) (26)
An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram (2000) (26)
Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram (1995) (26)
Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder (2020) (26)
Late-Life Depression: Rationalizing Pharmacological Treatment Options (2002) (26)
Chairman's overview. The place of reboxetine in antidepressant therapy. (1998) (25)
Fluvoxamine in the treatment of obsessive compulsive disorder (1992) (25)
Pregabalin for the treatment of generalised anxiety disorder (2006) (25)
SSRIs in depression and anxiety (2001) (25)
Economic Analysis of Treating Depression with Nefazodone v. Imipramine (1996) (25)
The specificity of the zimelidine reaction. (1989) (25)
Temperament and character influence on depression treatment outcome. (2019) (25)
Psychopharmacology of depression (1994) (25)
The Benefits and Risks of 5-HT Uptake Inhibitors in Depression: Chairman's Introduction (1988) (25)
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. (2018) (25)
Antidepressants in long-term treatment. (1994) (24)
Desvenlafaxine for the Prevention of Relapse in Major Depressive Disorder: Results of a Randomized Trial (2010) (24)
Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials (2014) (24)
Selective Serotonin Reuptake Inhibitors in Older Patients (1997) (23)
Prophylaxis in recurrent unipolar depression: a new indication for treatment studies (1989) (23)
Fast‐onset antidepressants (1997) (22)
Efficacy, safety, and indications for tricyclic and newer antidepressants (1994) (22)
Psychopharmacology of panic (1993) (22)
The Evidence for 20 mg a day of Fluoxetine as the Optimal Dose in the Treatment of Depression (1988) (22)
Placebo‐controlled efficacy of antidepressants in continuation treatment (1994) (22)
The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study (2016) (21)
Social phobia: diagnosis, severity and implications for treatment (1999) (20)
Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. (1980) (19)
Effectiveness of Venlafaxine, Extended Release Formulation, in the Short-Term and Long-Term Treatment of Generalized Anxiety Disorder: Results of a Survival Analysis (2002) (18)
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder (2013) (18)
Measurement of serum drug levels in the assessment of antidepressants. (1980) (18)
Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study (2010) (17)
Pharmacological specificity is not the same as clinical selectivity. (1987) (17)
Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment (2020) (16)
Evaluation of depressive symptoms in patients with coronary artery disease using the Montgomery Åsberg Depression Rating Scale (2012) (16)
Pharmacokinetics and efficacy of maprotiline and amitriptyline in endogenous depression: a double-blind controlled trial. (1980) (16)
Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients (2004) (16)
Neuroendocrine responses to intravenous L-tryptophan in obsessive compulsive disorder. (1994) (16)
Obsessive compulsive disorder is not an anxiety disorder (1993) (15)
Diarrhoea during treatment with clozapine: association with lymphocyte count. (1992) (15)
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder (2009) (15)
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance (2017) (15)
Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development (2006) (15)
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study (2013) (15)
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram (2015) (15)
Maprotiline, nomifensine, mianserin, zimelidine: A review of antidepressant efficacy in in-patients (1980) (15)
Mianserin plasma levels and differential clinical response in endogenous and reactive depression. (1978) (14)
Prediction of Steady‐State Plasma Concentrations and Individual Dosage Regimens of Tricyclic Antidepressants from a Single Test Dose (1982) (14)
Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients. (2013) (14)
Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample (2015) (14)
UNWANTED EFFECTS OF FLUPHENAZINE ENANTHATE AND DECANOATE (1979) (14)
The risk of suicide with antidepressants. (1988) (14)
Plasma levels and clinical response with imipramine in a study comparing efficacy with mianserin and nomifensine. (1983) (14)
Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression (1992) (14)
Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression. (1992) (13)
Amitriptyline plasma concentrations and clinical response. (1979) (13)
Pharmacotherapy in the Prevention of Suicidal Behavior (1992) (13)
The benefits and risks of 5-HT uptake inhibitors in depression. (1988) (13)
Age, depression and tricyclic antidepressant levels (1979) (13)
Early response with clomipramine in obsessive compulsive disorder — A placebo controlled study (1990) (13)
Long‐term management of obsessive‐compulsive disorder (1996) (13)
Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder (2008) (12)
Single oral dose pharmacokinetics of clomipramine in depressed patients. (1980) (12)
Treatment‐resistant Depression (2013) (12)
Minaprine and dose response in depression. An investigation of two fixed doses of minaprine compared with imipramine. (1991) (12)
The place of obsessive compulsive disorder in the diagnostic hierarchy (1992) (11)
Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder (2010) (11)
Are 2-week trials sufficient to indicate efficacy? (1995) (11)
Measurement of change in psychiatric illness: new obsessional, schizophrenia and depression scales. (1980) (11)
Montgomery-Asberg Depression Rating Scale (2012) (10)
The psychopharmacology of borderline personality disorders. (1987) (10)
295 – A double blind comparison of antidepressant efficacy of zimelidine, a new 5 HT uptake inhibitor with amitriptyline (1978) (10)
Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder. (2006) (10)
Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. (2014) (9)
Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features. (2013) (9)
The clinical profile of mianserin (1991) (9)
Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy (2013) (9)
Development of new treatments for depression. (1985) (9)
Mianserin in the Prophylaxis of Suicidal Behaviour: a Double Blind Placebo Controlled Trial (1983) (9)
Definitions and Predictors of Treatment‐resistant Depression (2013) (9)
The place of reboxetine in antidepressant therapy (1998) (9)
Suicide prevention and serotonergic drugs (1993) (9)
Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. (1998) (9)
The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study (2017) (8)
Recovery from depressive illness does fit an exponential model. (1996) (8)
Serotonin, sertraline and depression (1995) (8)
Are the ICD-10 or DSM-5 diagnostic systems able to define those who will benefit from treatment for depression? (2016) (8)
Mixed, melancholic, and anxious features in depression: a cross-sectional study of sociodemographic and clinical correlates. (2014) (8)
Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. (2013) (8)
The Brief Depression Scale - Reliability and validity of a new self-rating depression scale (2000) (8)
Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression (2015) (8)
Moclobemide in the treatment of social phobia. (1996) (8)
Profile of antidepressant action of zimelidine and norzimelidine compared with amitriptyline. (1982) (8)
Do some antidepressants promote suicide? (2004) (7)
Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis (2017) (7)
Acute hypertensive episode induced by sulpiride – a case report (1989) (7)
Pharmacological differences between brief and major depressions (1993) (7)
Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels (2014) (6)
Milnacipran: recent findings in depression (2010) (6)
Features of recurrent brief depression. (1992) (6)
First International Exchange on Bipolar Disorder. (2000) (6)
Family history of major depression and residual symptoms in responder and non-responder depressed patients. (2014) (6)
Lithium, Thyroid Hormones and Further Augmentation Strategies in Treatment‐resistant Depression (2013) (6)
A double blind comparison of lithium carbonate and ludiomil in the prophylaxis of unipolar affective illness. (1976) (6)
[Biological treatments in obsessive-compulsive disorder]. (1990) (6)
Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. (2018) (6)
Single dose pharmacokinetic data on zimelidine in depressed patients (1980) (6)
The nonselective effect of selective antidepressants. (1982) (6)
Evaluation of MADRS severity thresholds in patients with bipolar depression. (2021) (5)
Noradrenergic symptom cluster in depression (2011) (5)
Are higher doses more effective in OCD? (1994) (5)
The Role of Atypical Antipsychotics in Inadequate‐response and Treatment‐resistant Depression (2013) (5)
Oxford Textbook of Clinical Pharmacology and Drug Therapy (1993) (5)
Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes (2010) (5)
Social phobia: the need for treatment (1997) (5)
patients with mood disorders (2009) (5)
Letter to the Editor. Jaundice associated with the use of risperidone in a case of presenile dementia (1996) (5)
Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder (2014) (5)
Cardiovascular effects of amitriptyline, mianserin and zimelidine in depressed patients. (1980) (5)
Economic considerations in the prescribing of third-generation antidepressants (2012) (5)
The serotonin transporter and the activity regulated cytoskeleton‐associated protein genes in antidepressant response and resistance: 5‐HTTLPR and other variants (2018) (5)
Depression in the elderly: pharmacokinetics of antidepressants and death from overdose. (1990) (5)
Opinion paper: poor response to treatment of depression in people in high occupational levels (2018) (5)
The need for long term treatment of depression (1997) (5)
Guidelines in major depressive disorder, and their limitations (2006) (4)
Handbook of Generalised Anxiety Disorder (2011) (4)
Social adjustment among treatment responder patients with mood disorders. (2013) (4)
Handbook of Generalised Anxiety Disorder (2011) (4)
Failure to demonstrate prophylactic efficacy of dothiepin (1993) (4)
Brief unipolar depressions: is there a bipolar component? (1992) (4)
Comparative efficacy of antidepressants. Discussion (1992) (4)
Pharmacotherapy for Mood, Anxiety, and Cognitive Disorders (2000) (4)
Relative Toxicity of Antidepressants Using Reports Independent of Observer Bias (1990) (4)
Suicide and Antidepressants (2012) (4)
Phenomenology and Differential Diagnostic Status of Obsessive-Compulsive Disorder (1992) (4)
The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. (2021) (3)
Antidepressant or antidepressant plus placebo effect? (2015) (3)
Cardiovascular effects of amitriptyline, mianserin and zimelidine in depressed patients (1980) (3)
Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression (2020) (3)
PMH42: TREATMENT OF DEPRESSION: ESCITALOPRAM HAS SIMILAR EFFICACY BUT LOWER COSTS COMPARED TO VENLAFAXINE XR (2003) (3)
Letter: Tryptophan in depression. (1974) (3)
Lack of efficacy of moclobemide or imipramine in the treatment of recurrent brief depression: results from an exploratory randomized, double-blind, placebo-controlled treatment study (2014) (3)
Relapse prevention with antidepressants (1993) (3)
The prevention of suicidal acts in high-risk patients. (1984) (3)
Efficacy of nefazodone in the treatment of depression (1996) (3)
The Provocation and Prevention of Suicide Attempts (1992) (3)
Predictive factors of remission for treatment-resistant major depressive disorder (MDD) during treatment withextended-release quetiapine fumarate(quetiapine XR) (2010) (2)
Developing cross-national CME for mental disorders in Europe* (2001) (2)
THE USE OF THE MADRS IN MEASURING PROFILES OF ACTION (1984) (2)
STATUS OF LITHIUM PATIENTS AS BLOOD-DONORS (1975) (2)
PLASMA AMITRIPTYLINE AND CLINICAL EFFECT (1978) (2)
Citalopram is effective in obsessive compulsive disorder: Results of a double-blind, placebo-controlled trial (1999) (2)
Citalopram in the treatment of depression. (1995) (2)
Depression with high levels of anxiety. (2019) (2)
Focus on social functioning in depression. (1998) (2)
Antidepressants in the prophylactic treatment of recurrent major depression (1994) (2)
Supersensitivity and nomifensine in depressed patients. (1982) (2)
Prophylactic treatment of depression. (1994) (1)
The Role of Psychotherapy in the Management of Treatment‐resistant Depression (2013) (1)
Subject Index Vol. 22, 1989 (1989) (1)
Pregabalin for the treatment of generalized anxiety disorder (GAD): Efficacy and safety in elderly patients (2007) (1)
Genetics of Treatment‐resistant Depression (2013) (1)
Discontinuation symptoms in affective disorders (2005) (1)
Evidence-based prescribing of antidepressants (2003) (1)
Prediction of plasma levels and clinical response in depression (1981) (1)
P.3.040 Relapse in social anxiety disorder (SAD): Costs and quality of life (2003) (1)
Depression as a Public Health Issue (1989) (1)
Dose response relationship of citalopram 20 mg, citalopham 40 mg and placebo in the treatment of moderate and severe depression (1992) (1)
Is long-term treatment effective in OCD? (1993) (1)
S-38-1 Treatment of social phobia (1996) (1)
Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. (2021) (1)
Is There a Role for Switching Antidepressants in Treatment‐resistant Depression? (2013) (1)
629 – PLASM CONCENTRATIONS OF CLOMIPRAMINE AND CLINICAL RESPONSE IN DEPRESSED PATIENTS (1978) (1)
Montgomery-Asberg Depression Rating Scale (MADRS) 1979 (1992) (1)
LONG TERM TREATMENT WITH SSRIs (1992) (1)
SSRIs in Obsessive‐Compulsive Disorder (2001) (1)
Efficacious and Safe Psychotropics Not Available in the United States (1996) (1)
Treatment response in obsessive compulsive disorder (1991) (1)
Selective serotonin reuptake inhibitors in psychiatric practice (1992) (1)
PMH24: COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS PLACEBO IN RELAPSE PREVENTION IN PATIENTS WITH SOCIAL ANXIETY DISORDER (2003) (1)
Promising psychopharmacologic medications not available in the USA (1995) (1)
Lofepramine, desipramine and abnormal tests of liver function: a case report. (1990) (1)
Drug treatment of suicidal behaviour. (1982) (1)
Theoretical and practical implications of a controlled trial of an alpha 2-adrenoceptor antagonist in the treatment of depression. (1989) (1)
L-101 Acute and long term treatment — How long do you need to treat depression? (1996) (0)
Ssris and Deliberate Self-harm Ssris and Deliberate Self-harm (0)
Foundations of Clinical Psychiatry. By Joseph M. StrayhornJr . London: Year Book Medical Publishers. 1982. Pp 590. £26.50 (1982) (0)
P.2.f.015 A prospective study of escitalopram in treatment resistant depression not responding to venlafaxine (2013) (0)
P.2.f.011 Socio-demographic and clinical predictors of non response/non remission in treatment resistant depressed patients: a systematic review (2014) (0)
Clinical predictors of antidepressant response and remission in treatment resistant depression (2007) (0)
T role of noradrenaline and selective noradrenaline reuptake inhibition in (2002) (0)
PMH25: SOCIAL ANXIETY DISORDER: EFFECT OF RELAPSE ON COSTS AND QUALITY OF LIFE (2003) (0)
PHARMACOKINETIC TREATMENT ISSUES IN THE ELDERLY (1984) (0)
SSRIs APPEAR TO BE MORE EFFECTIVE THAN IMIPRAMINE IN SEVERE DEPRESSION IN PLACEBO CONTROLLED STUDIES (1992) (0)
PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers (2016) (0)
Relevant Selectivity of Antidepressants (1985) (0)
THE SELECTIVE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS (1992) (0)
Eﬃcacy and safety of 30 mg/d and 45 mg/d nemiﬁtide compared to placebo in major depressive disorder (2006) (0)
Selective serotonin reuptake inhibitors: Therapeutic alternatives to the tricyclics in the treatment of major depression (1995) (0)
[Prevention of suicide]. (1983) (0)
Editorial (1990) (0)
Treatment of Affective Disorders (1996) (0)
Westcotes Hospital, Leicester Flooding and Implosive Therapy: Direct Therapeutic Exposure in Clinical Practice. By PATRICK A (1984) (0)
[A new antidepressive agent. Mianserin hydrochloride (Tolvin)]. (1978) (0)
P.2.b.026 Social adjustment among therapy responder patients with mood disorders (2013) (0)
P.3.026 Clinical and genetic predictors of antidepressant response and remission in treatment-resistant depression (2012) (0)
Which treatments, when and for how long? (2009) (0)
Presenting features of generalised anxiety disorder (2009) (0)
Treatment of Obsessive-Compulsive Disorder (1999) (0)
Introduction (1968) (0)
Psychotropic Drug Directory 1993 (1993) (0)
Introduction. Understanding Depression and Its Treatment: Restoration of Chemical Balance or Creation of Conditions Promoting Recovery? (2000) (0)
70-4 Dosage of antidepressants and long term treatment of depression (1997) (0)
THE DEVELOPEMENT OF NEW TREATMENT FOR DEPRESSION (1984) (0)
Regional Baseline Symptom Patterns in Major Depressive Disorder Trials (2013) (0)
Lead editorial – Major depressive disorder (2012) (0)
Subject Index Vol. 48, 2002 (2002) (0)
Q Does pregabalin or venlafaxine treatment reduce symptoms of generalised anxiety disorder compared with placebo (2014) (0)
Burden of generalised anxiety disorder (2009) (0)
4. Is There a Role for Switching Antidepressants in Treatment-resistant Depression? (2013) (0)
Comorbidity of generalised anxiety disorder with other conditions (2009) (0)
The prediction of tricyclic antidepressant plasma concentrations. (1980) (0)
Pitfalls in assessing efficacy and side-effects of antidepressants. (1989) (0)
P.2.078 Discontinuation symptoms in social anxiety disorder, general anxiety disorder, and major depressive disorder (2005) (0)
How common is generalised anxiety disorder (2009) (0)
Dose and profile of citalopram in the management of depressive illness (1993) (0)
The Prevention of Attempts in High Risk Suicidal Patients (1985) (0)
Genetic variants within neuronal cell adhesion genes and antidepressant response in three independent groups (2015) (0)
Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693). (2009) (0)
Clinicians manual on generalized anxiety disorder (2006) (0)
Risk-Benefit Assessment of Deaths from Adverse Drug Reactions and Overdosage with Antidepressants (1989) (0)
Discontinuation symptoms in social anxiety disorder, generalised anxiety disorder, and major depressive disorder (2005) (0)
Farewell message from the Founding Editors (2009) (0)
Contents Vol. 48, 2002 (2002) (0)
Antidepressants and heart disease (1984) (0)
SCIENTIFIC ADVANCES AND RISK BENEFIT ISSUES IN THE TREATMENT OF DEPRESSIVE DISORDERS (1992) (0)
The changing concept of generalised anxiety disorder (2009) (0)
9 INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS (2009) (0)
PS87. An update on prediction of treatment outcome in treatment resistant depression (2016) (0)
90-132 Severe depression: The choice of antidepressant therapy (1997) (0)
Attrition in treatment-resistant depression: predictors and clinical impact. (2019) (0)
Extends-Release quetiapine fumarate mono therapy and quetiapine XR or lithium add-on to antidepressants in patients with treatment-resistant major depressive disorder (2013) (0)
Measuring the severity of generalised anxiety disorder (2009) (0)
Black bile and noradrenaline: alternative views on the pathogenesis of depression (1992) (0)
PR 04 . ECNP / AEP SYMPOSIUM PR 04 . 01 Factors associated to resistant depression (2007) (0)
Hypersensitivity to zimelidine without cross reactivity to fluoxetine. (1989) (0)
Erratum to: Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder (2013) (0)
P.2.f.006 Temperament and character inventory and response to antidepressant treatment (2015) (0)
Clinical and genetic predictors of antidepressant response and remission in treatment-resistant depression (2012) (0)
Foreword (2004) (0)
Summary statement First International Exchange on Bipolar Disorder (2000) (0)
Letter: Status of lithium patients as blood-donors. (1975) (0)
PW01-24 - Evaluation of the Effects of Quetiapine XR Monotherapy According to MDD Severity: Pooled Data From 4 Placebo-controlled Trials (2010) (0)
Obsessive compulsive disorder : papers presented at the Osbessive Compulsive Disorder Symposia held in Florence, June 1991 and Monte-Carlo, October 1991 and other invited work (1992) (0)
S-17-4 Are there more effective drug treatments for obsessive compulsive disorders? (1995) (0)
Editorial (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stuart A. A. Montgomery?

Stuart A. A. Montgomery is affiliated with the following schools:

St Mary's Hospital Medical School

Stuart A. A. Montgomery's Academic­Influence.com Rankings

Why Is Stuart A. A. Montgomery Influential?

Stuart A. A. Montgomery's Published Works

Published Works

What Schools Are Affiliated With Stuart A. A. Montgomery?

Stuart A. A. Montgomery's AcademicInfluence.com Rankings